PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen’s commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution.
David Lin brings to UroGen a wealth of experience garnered from a distinguished career in the pharmaceutical industry. Prior to joining UroGen, David held several key leadership positions at Bristol Myers Squibb, where he played pivotal roles in driving the success of various initiatives. Notably, as Head of U.S. Cell Therapy, David led the successful launch of two CAR T therapies, showcasing his expertise in bringing innovative therapies to market. Additionally, his tenure as Head of Worldwide Cardiovascular contributed significantly to the global cardiovascular franchise, including expansion through the MyoKardia acquisition.
“As we enter the next stage in building a long-term growth company, we are thrilled to welcome David to the UroGen team,” said Liz Barrett, President and CEO of UroGen Pharma. “His extensive experience and proven track record of commercial success will be invaluable as we advance our mission of bringing innovative therapies to patients in need. With David’s leadership, we are confident in our ability to maximize the commercial potential of JELMYTO and our expanding pipeline.”
Before his time at Bristol Myers Squibb, David served as Global Head of Surgery and Perioperative Care at The Medicines Company, demonstrating his diverse experience across different sectors of the healthcare industry. His career journey also includes various leadership roles at Johnson & Johnson, where he made impactful contributions to pharmaceuticals, medical devices, and consumer businesses.
David Lin expressed his enthusiasm about joining UroGen, stating, “I am honored to join UroGen at such an exciting time in the company’s evolution. I look forward to working closely with the team to drive commercial success and ultimately make a meaningful difference in the lives of patients with urothelial cancers.”
David is an alumnus of Cornell University, where he earned his Bachelor of Arts in Economics, and Duke University, where he completed his Master of Business Administration (MBA). Beyond his professional endeavors, David is actively engaged in mentoring start-up businesses in life sciences as a member of the Canadian Technology Accelerator and serves as a Strategic Advisor to ChroniSense Medical, a clinical-stage medical technology company.
Jeff Bova will be stepping down as Chief Commercial Officer on June 3 as he pursues new opportunities. We are incredibly grateful for the work he did here at UroGen.
For more information about UroGen Pharma and its portfolio of urological solutions, please visit www.urogen.com.
About JELMYTO
JELMYTO® (mitomycin) for pyelocalyceal solution is a mitomycin-containing reverse thermal gel containing 4 mg mitomycin per mL gel indicated for the treatment of adult patients with low-grade-UTUC (LG-UTUC). It is approved for adult patients with LG-UTUC. JELMYTO is a viscous liquid when cooled and becomes a semi-solid gel at body temperature. The drug slowly dissolves over four to six hours after instillation and is removed from the urinary tract by normal urine flow and voiding. It is approved for administration in a retrograde manner via ureteral catheter or antegrade through nephrostomy tube. The delivery system allows the initial liquid to coat and conform to the upper urinary tract anatomy. The eventual semisolid gel allows for chemoablative therapy to remain in the collecting system for four to six hours without immediately being diluted or washed away by urine flow.
About UGN-102
UGN-102 (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, currently in Phase 3 development for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. Utilizing UroGen’s proprietary RTGel® technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting. Assuming positive findings from the durability of response endpoint from the ENVISION Phase 3 study, UroGen anticipates completing its New Drug Application (NDA) submission for UGN-102 in Q3 2024 with a potential U.S. Food and Drug Administration (FDA) decision as early as the first quarter of 2025.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X (Twitter), @UroGenPharma.
